2019
DOI: 10.1136/jim-2018-000901
|View full text |Cite
|
Sign up to set email alerts
|

Long-term efficacy of rifaximin to manage the symptomatic uncomplicated diverticular disease of the colon

Abstract: Although rifaximin is currently advised in managing symptomatic uncomplicated diverticular disease (SUDD) of the colon, no long-term data are available. This retrospective study assessed the outcome of a large cohort of patients with SUDD, treated with rifaximin, during an 8-year follow-up. The study group (group A) included 346 patients with SUDD (median age 64 years, IQR 58–69, 62.4% females), treated with rifaximin 800 mg/d for 7 days every month. The control group (group B) included 470 patients with SUDD … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
22
0
4

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
2

Relationship

4
6

Authors

Journals

citations
Cited by 25 publications
(27 citation statements)
references
References 18 publications
1
22
0
4
Order By: Relevance
“…In addition, rifaximin is also very effective in the treatment of small intestine bacterial overgrowth (SIBO, the most widely detected form of gut dysbiosis) 141 and related (organic and functional) gastrointestinal disorders 142 and safe in clinical practice 143 .…”
Section: [Au: Moved Section On Dica Classification Below For Flow]mentioning
confidence: 99%
“…In addition, rifaximin is also very effective in the treatment of small intestine bacterial overgrowth (SIBO, the most widely detected form of gut dysbiosis) 141 and related (organic and functional) gastrointestinal disorders 142 and safe in clinical practice 143 .…”
Section: [Au: Moved Section On Dica Classification Below For Flow]mentioning
confidence: 99%
“…This also means that SUDD patients often require recurrent therapeutic courses to control symptoms. In this way, long-term treatment is warranted, and both mesalazine and rifaximin proved to be effective in controlling long-term symptoms [ 18 , 19 ].…”
Section: Discussionmentioning
confidence: 99%
“…In recent years, new insights have emerged regarding the qualitative and the quantitative changes in microbiota composition and diversity, which appear to be crucial for the occurrence and the persistence of symptoms in patients with colonic diverticulosis [ 11 ]. Consistently, the poorly absorbable drug rifaximin, which favours the growth of bacteria beneficial to the host without altering its overall composition, has been used with success in the prevention of exacerbations of colonic diverticulosis [ 12 , 13 ]. In addition, rifaximin is able to down-regulate the inflammatory response triggered by the gut microbes through inhibition of the activation of the transcription factor nuclear factor-κB and of the induction of inflammatory cytokines, such as Tumor Necrosis Factor and interleukin-1β [ 14 , 15 ].…”
Section: Discussionmentioning
confidence: 99%